https://www.facebook.com/106953565356755/

Indis Healthcare, Kundli Road, Industrial Area, Kundli, Rai (2026)

30/01/2026

INDIS Launched New Product
Hepanate™ Sachets

Advanced Liver Support with L-Ornithine L-Aspartate Granules

INDIS is pleased to announce the launch of its new premium liver care product, Hepanate™ Sachets, formulated with L-Ornithine L-Aspartate Granules. This launch further strengthens the INDIS portfolio of high-quality, trusted pharmaceutical products.

Hepanate™ is developed to support liver function and assist in the management of various liver-related disorders, offering clinicians an effective and patient-friendly oral therapy.

⸻

🔹 About Hepanate™

Hepanate™ contains L-Ornithine L-Aspartate (LOLA), a clinically proven combination known for its role in ammonia detoxification and liver metabolism. It helps improve hepatic function and supports recovery in chronic liver conditions.

⸻

🔹 Key Therapeutic Benefits

✔ Adjuvant in the treatment of liver diseases such as cirrhosis and fatty liver
✔ Effective in the management of hepatic encephalopathy
✔ Helps reduce elevated blood ammonia levels
✔ Supports liver detoxification and regeneration
✔ Improves overall liver function and patient well-being

⸻

🔹 Product Details
• Brand Name: Hepanate™ Sachets
• Composition: Each 5 g sachet contains L-Ornithine L-Aspartate 3 g
• Dosage Form: Granules for oral administration
• Packing: 20 Sachets × 5 g
• Case Size: 100 Boxes
• Manufactured By: Windlas Biotech Ltd.

⸻

🔹 Why Hepanate™?

✔ Proven liver-support formula
✔ Easy-to-consume oral sachets
✔ Suitable for long-term liver management
✔ Trusted INDIS quality standards
✔ Ideal for gastroenterology and physician practice

⸻

🔹 Conclusion

With the launch of Hepanate™ Sachets, INDIS continues its commitment to delivering reliable, effective, and patient-centric healthcare solutions. Hepanate™ stands as a valuable addition for physicians managing liver disorders and metabolic complications related to hyperammonemia.

Contact: +91 92892 88384
✉️ Email:indishelthcare@gmail.com

30/01/2026

INDIS LAUNCHED NEW PRODUCT
Brand...

Texadis™
– A Trusted Solution for Effective Bleeding Control

In modern medical practice, timely and effective control of bleeding plays a crucial role in saving lives. During surgeries, childbirth, trauma, or cases of excessive menstrual bleeding, clinicians require a reliable and fast-acting injectable therapy.
Texadis™ (Tranexamic Acid Injection IP 500 mg/5 ml) is designed to meet this critical need with proven efficacy and safety.

⸻

🔹 What is Texadis™?

Texadis™ contains Tranexamic Acid, a well-established antifibrinolytic agent that helps prevent the breakdown of blood clots, thereby reducing and controlling excessive bleeding.

⸻

🔹 Key Indications

1️⃣ Control of Bleeding in Surgery
Texadis™ is widely used during surgical procedures to minimize excessive blood loss and improve patient outcomes.

2️⃣ Postpartum Hemorrhage (PPH)
It plays a vital role in the management of excessive bleeding following childbirth, helping to reduce maternal morbidity.

3️⃣ Traumatic & Internal Bleeding
In cases of trauma or internal injuries, Texadis™ provides rapid and effective control of bleeding.

4️⃣ Heavy Menstrual Bleeding
Texadis™ is also effective in managing abnormal or excessive menstrual blood loss in women.

⸻

🔹 Composition & Packing
• Brand Name: Texadis™
• Composition: Tranexamic Acid Injection IP 500 mg / 5 ml
• Packing: 10 × 5 × 5 ml Ampoules
• Route of Administration: IM / IV use only

⸻

🔹 Why Choose Texadis™?

✔ Rapid and reliable action
✔ Effective in multiple bleeding conditions
✔ Manufactured under strict quality standards
✔ Trusted choice for healthcare professionals
✔ Economical and channel-friendly packaging

⸻

🔹 Conclusion

Texadis™ stands as a safe, effective, and dependable injectable therapy for bleeding control. Whether in surgical settings, obstetric care, or emergency management, Texadis™ supports clinicians in delivering timely and confident patient care.

🔹 Dosage: As directed by the physician

Contact: +91 92892 88384
✉️ Email:indishelthcare@gmail.com

26/01/2026

🌸 गणतंत्र दिवस की हार्दिक शुभकामनाएँ 🌸
🇮🇳 ————- 🇮🇳 ———- 🇮🇳 ———- 🇮🇳

🇮🇳 26 जनवरी – गणतंत्र दिवस 🇮🇳

एक ऐसा दिन, जो हमें यह स्मरण कराता है कि
भारत की शक्ति उसकी एकता, विविधता और जिम्मेदारी में है।

आइए, संविधान के मूल्यों के साथ एक स्वस्थ, समरस और सशक्त राष्ट्र निर्माण का संकल्प लें।

गणतंत्र दिवस की हार्दिक शुभकामनाएँ 🌸

23/01/2026

🌼 शुभ बसंत पंचमी 🌼
वाणी का संस्कार : बसंत में खिलती आत्मा

भारतीय आध्यात्मिक परंपरा में वाणी केवल शब्द नहीं,
आत्मा की ऋतु मानी गई है।
जैसी वाणी — वैसा मन,
और जैसा मन — वैसा ही जीवन।

आज बसंत पंचमी है —
शीत के जड़त्व से निकलकर
चेतना, कोमलता और प्रकाश की ओर बढ़ने का दिन।

⸻

माघ मास की यह शीतल सुबह
हमें केवल ठंड नहीं देती,
यह सिखाती है —
शांत रहो, संयमित रहो, सौम्य बनो।

इसी दिन वाणी की अधिष्ठात्री
माँ सरस्वती की आराधना होती है,
जो बताती हैं कि
ज्ञान ऊँचे स्वर से नहीं,
शुद्ध शब्दों से प्रकट होता है।

⸻

गरुड़ पुराण चेतावनी देता है —
कटु वाणी बुद्धि को क्षीण कर देती है।
यह केवल ग्रहों की बात नहीं,
यह मनुष्य की आंतरिक आग की बात है।

जिस दिन हम सरस्वती की पूजा करें,
और उसी दिन वाणी अशुद्ध रहे —
तो साधना केवल औपचारिक रह जाती है।

⸻

संत कबीर की अमर सीख याद रखें —

“मीठी वाणी बोलिए, मन का आपा होय।
औरन को सीतल करे, खुद ही सीतल होय॥”

यही बसंत का सच्चा दर्शन है —
पहले स्वयं शीतल बनो,
तभी संसार में शांति फैलती है।

⸻

बसंत पंचमी हमें सिखाती है कि —
सबसे सुंदर पुष्प शब्दों के होते हैं,
और सबसे तीखा काँटा भी शब्द ही।

जो व्यक्ति
• क्रोध में मौन रखता है
• कटु शब्दों के स्थान पर मधुरता चुनता है
• वाणी को धर्म की मर्यादा में बाँधता है

वही सच्चे अर्थों में बसंत को जीता है।

⸻

🌼 आज का संकल्प 🌼

• वाणी से किसी को आहत नहीं करेंगे
• शब्दों से शीतलता फैलाएँगे
• और ज्ञान की देवी का सम्मान अपने बोल में प्रकट करेंगे

क्योंकि —
जो वाणी दूसरों को शीतल करे,
वही वाणी आत्मा को बसंत प्रदान करती है।

🌼 शुभ बसंत पंचमी 🌼

18/01/2026

INDIS LAUNCHED NEW PRODUCT
Brand...

Onditil®: Trusted Injectable Anti-Emetic for Effective Control of Nausea and Vomiting

Nausea and vomiting are common yet distressing symptoms associated with surgery, chemotherapy, radiotherapy, and various medical conditions. Prompt and reliable control of emesis is essential for patient comfort, recovery, and treatment compliance. Onditil®, containing Ondansetron Injection IP 4 mg/2 ml, is a proven injectable anti-emetic designed to deliver rapid and effective relief in clinical and hospital settings.

Product Overview …

Onditil® is an injectable formulation of Ondansetron, a well-established 5-HT3 receptor antagonist, intended for IM/IV use only. It is widely used in hospitals for the prevention and treatment of nausea and vomiting, especially when oral therapy is not feasible or effective.

Mechanism of Action …

Ondansetron works by selectively blocking serotonin (5-HT3) receptors in the central nervous system and gastrointestinal tract. By inhibiting serotonin-mediated stimulation of the vomiting center, Onditil®:
• Rapidly controls nausea and vomiting
• Reduces emetic episodes associated with surgery and chemotherapy
• Provides sustained anti-emetic protection

Therapeutic Indications …

Onditil® is commonly indicated for:
• Prevention and treatment of post-operative nausea and vomiting
• Chemotherapy- and radiotherapy-induced nausea and vomiting
• Acute nausea and vomiting due to medical or surgical causes
• Supportive care in hospitalized and critically ill patients

Key Benefits ….
• Rapid and effective control of nausea and vomiting
• Proven efficacy in post-operative and chemotherapy-induced emesis
• Injectable formulation for emergency and inpatient use
• Well-tolerated with a strong safety profile
• Enhances patient comfort and recovery

Composition & Presentation ….
• Composition: Ondansetron Injection IP 4 mg/2 ml
• Packing: 20 × 5 × 2 ml ampoules
• Route of Administration: IM / IV only
• Dosage: As directed by the physician

Quality & Manufacturing …

Onditil® is manufactured by Heilsa Life Sciences Pvt. Ltd. under strict quality control standards and marketed by Indis Healthcare in association with Ind-Swift Laboratories Limited. Each ampoule is produced to ensure consistency, safety, and clinical reliability.

Clinical Relevance ….

Injectable ondansetron remains a cornerstone therapy in hospitals, surgical units, oncology departments, and emergency care. Onditil® supports clinicians in managing emesis effectively, improving patient outcomes and overall treatment experience.

Conclusion ….

With its rapid onset of action, proven anti-emetic efficacy, and injectable convenience, Onditil® stands as a dependable solution for the management of nausea and vomiting in diverse clinical settings.

Onditil® – Trusted Injectable Anti-Emetic Solution

Contact: +91 92892 88384
✉️ Email:indishelthcare@gmail.com

18/01/2026

INDIS LAUNCHED NEW PRODUCT
Brand...

Ranituc™: Effective Injectable Therapy for Gastric Hyperacidity and Ulcer Management

Gastric hyperacidity and peptic ulcer disease are common gastrointestinal conditions that often require prompt and effective acid-suppressive therapy, especially in hospitalized and critically ill patients. Ranituc™, containing Ranitidine Injection IP 25 mg, is a trusted injectable formulation designed to provide rapid relief from acid-related disorders under medical supervision.

Product Overview …

Ranituc™ is an H2-receptor antagonist available in injectable form for IM/IV use only. It works by inhibiting gastric acid secretion, making it highly effective in the management of acute and severe acid-related conditions where oral therapy is not feasible.

Mechanism of Action …

Ranitidine selectively blocks histamine H2 receptors in the gastric parietal cells, thereby:
• Reducing basal and stimulated gastric acid secretion
• Decreasing gastric volume and acid concentration
• Promoting healing of gastric and duodenal ulcers

This targeted action makes Ranituc™ a reliable option in emergency and inpatient care.

Therapeutic Indications ….

Ranituc™ is commonly used in the management of:
• Gastric hyperacidity
• Peptic ulcer disease
• Gastroesophageal reflux disease (GERD)
• Stress-related mucosal damage
• Prevention of upper gastrointestinal bleeding in critically ill patients

Key Benefits ….
• Rapid reduction of gastric acid secretion
• Provides quick relief from ulcer-related symptoms
• Helps prevent bleeding associated with stress ulcers
• Suitable for patients unable to take oral medications
• Well-established safety and efficacy profile

Composition & Presentation …
• Composition: Ranitidine Injection IP 25 mg
• Packing: 20 × 5 × 2 ml ampoules
• Route: For IM/IV use only
• Dosage: As directed by the physician

Quality & Manufacturing …

Ranituc™ is manufactured by Heilsa Life Sciences Pvt. Ltd. in compliance with stringent quality standards and marketed by Indis Healthcare in association with Ind-Swift Laboratories Limited. Each ampoule is produced to ensure consistency, safety, and therapeutic reliability.

Clinical Relevance ….

Injectable ranitidine plays an important role in hospital settings, particularly in acute care, surgical wards, and intensive care units. Ranituc™ supports clinicians in managing acid-related complications efficiently while ensuring patient safety.

Conclusion …

With its rapid action, proven mechanism, and injectable convenience, Ranituc™ stands as a dependable choice for the management of gastric hyperacidity and ulcer-related conditions. It reflects a balance of clinical effectiveness, safety, and quality—making it a valuable addition to hospital and critical care protocols.

Ranituc™ – Trusted Injection for Gastric Ulcer Management

Contact: +91 92892 88384
✉️ Email:indishelthcare@gmail.com

18/01/2026

INDIS LAUNCHED NEW PRODUCT
Brand...

Duozap™: Dual Bronchodilator Therapy for COPD & Asthma

Respiratory conditions such as asthma and Chronic Obstructive Pulmonary Disease (COPD) significantly impact breathing and overall quality of life. Patients often experience breathlessness, chest tightness, and wheezing, which require fast and effective bronchodilator therapy. Duozap™, a combination of Levosalbutamol (1.25 mg) and Ipratropium Bromide (500 mcg), is designed to provide reliable and rapid relief through nebulisation.

Product Overview

Duozap™ is available as respules for inhalation only, intended for use with a nebuliser. Its dual-action formulation works synergistically to open the airways, improve airflow, and ease breathing in patients with obstructive airway diseases.

Mechanism of Action
• Levosalbutamol, a selective β2-agonist, relaxes bronchial smooth muscles, providing quick bronchodilation.
• Ipratropium Bromide, an anticholinergic agent, reduces bronchoconstriction and helps maintain airway patency for a longer duration.

Together, these agents offer enhanced and sustained bronchodilation, resulting in better symptom control.

Key Benefits
• Rapid and effective bronchodilation
• Relief from symptoms of asthma and COPD
• Dual-action formula for improved and prolonged relief
• Nebulised delivery ensures direct action in the lungs
• Suitable for pediatric, geriatric, and severe respiratory patients

Composition & Presentation
• Composition:
Levosalbutamol 1.25 mg
Ipratropium Bromide 500 mcg
• Packing: 8 × 5 × 2.5 ml respules
• Dosage: As directed by the physician

Quality & Manufacturing

Duozap™ is manufactured by AXA Parenterals Ltd. under stringent quality standards and marketed by Indis Healthcare in association with Ind-Swift Laboratories Limited. Each unit reflects consistency, safety, and therapeutic reliability.

Clinical Relevance

The combination of a β2-agonist and an anticholinergic makes Duozap™ a preferred choice in the management of acute and chronic obstructive airway conditions. Its nebulised form allows effective drug delivery, especially in patients who may have difficulty using inhalers.

Conclusion

With its proven dual bronchodilator combination and nebulised delivery system, Duozap™ stands as a dependable option for managing COPD and asthma. It helps improve breathing, reduce exacerbations, and enhance patient comfort when used under medical supervision.

Duozap™ – Dual Bronchodilator Treatment for COPD & Asthma

Contact: +91 92892 88384
✉️ Email:indishelthcare@gmail.com

18/01/2026

INDIS LAUNCHED NEW PRODUCT
Brand...

Budezap™: Effective Nebulised Therapy for Asthma and Respiratory Care

Respiratory disorders such as asthma and chronic inflammatory airway diseases require targeted, reliable, and patient-friendly treatment options. Budezap™, containing Budesonide Nebuliser Suspension BP 0.5 mg/2 ml, is a trusted inhalation therapy designed to deliver effective anti-inflammatory action directly to the lungs, ensuring better disease control and improved patient outcomes.

About the Product ….

Budezap™ is a preservative-free nebuliser suspension formulated for inhalation use only. It contains Budesonide, a well-established inhaled corticosteroid widely prescribed for the management of asthma and other chronic respiratory conditions.

By delivering medication directly to the respiratory tract, Budezap™ helps reduce airway inflammation while minimizing systemic exposure.

Mechanism & Therapeutic Role ….

Budesonide works by suppressing inflammatory responses in the airways, reducing swelling, mucus production, and bronchial hyper-responsiveness. Nebulised delivery ensures uniform drug distribution in the lungs, making it especially suitable for:
• Pediatric patients
• Elderly patients
• Patients unable to use inhalers effectively

Key Benefits of Budezap™
• Effective management of asthma and chronic respiratory disorders
• Direct delivery of medication to the lungs
• Preservative-free respules for enhanced safety
• Suitable for long-term respiratory care under medical supervision
• Improved patient compliance with nebuliser therapy

Composition & Presentation
• Composition: Budesonide Nebuliser Suspension BP 0.5 mg/2 ml
• Packing: 8 × 5 × 2 ml respules
• Form: Respules for inhalation only

Quality & Manufacturing ….

Budezap™ is manufactured by AXA Parenterals Ltd., adhering to stringent quality standards, and marketed under the trusted banner of Indis Healthcare in association with Ind-Swift Laboratories Limited. Each pack reflects a commitment to safety, consistency, and therapeutic reliability.

Clinical Confidence ….

Doctors across specialties rely on Budesonide nebulisation as a cornerstone therapy for controlling airway inflammation. Budezap™ supports clinicians in delivering evidence-based respiratory care while ensuring patient comfort and convenience.

Conclusion …

With its proven active ingredient, preservative-free formulation, and efficient nebulised delivery, Budezap™ stands as a dependable solution for asthma and chronic respiratory management. It represents a balance of clinical efficacy, safety, and patient-centric design—helping patients breathe easier and live better.

Budezap™ – Relief from Asthma and Respiratory Disorders

Contact: +91 92892 88384
✉️ Email:indishelthcare@gmail.com

14/01/2026

हैप्पी लोहड़ी और मकर संक्रांति
—————————————
लोहड़ी और मकर संक्रांति केवल पर्व नहीं, बल्कि आस्था, प्रकृति और परिश्रम के प्रति कृतज्ञता का उत्सव हैं।
लोहड़ी की अग्नि हमें नकारात्मकता त्याग कर नई ऊर्जा और उमंग के साथ आगे बढ़ने का संदेश देती है, वहीं मकर संक्रांति सूर्य के उत्तरायण होने के साथ नए आरंभ, समृद्धि और आशा का प्रतीक है।

ये पर्व हमें सिखाते हैं कि मेहनत, एकता और सकारात्मक सोच से जीवन में उजास आता है।
इस पावन अवसर पर आइए, हम सब मिलकर प्रेम, सौहार्द और खुशहाली को अपनाएँ।

आप सभी को लोहड़ी और मकर संक्रांति की हार्दिक शुभकामनाएँ।

12/01/2026

INDIS LAUNCHED NEW PRODUCT
Brand...
PRAZINATE - 600
Prazinate™ 600
Tablet

Praziquantel Tablets USP 600 mg

Indis Healthcare proudly presents Prazinate™ 600, a trusted anthelmintic formulation designed to support effective management of parasitic infections.

Formulated with Praziquantel USP 600 mg, Prazinate™ 600 is known for its proven efficacy, reliable performance, and consistent quality. Manufactured under strict quality standards, it offers confidence to healthcare professionals and value to patients.

Key Highlights:
✔ Praziquantel USP 600 mg
✔ Proven & trusted anthelmintic therapy
✔ Convenient blister packing
✔ Affordable & dependable quality

Prazinate™ 600 — delivering strength, quality, and reliability in parasite care.

📧 indishealthcare@gmail.com

05/01/2026

INDIS LAUNCHED NEW PRODUCT
Brand...

BOSVANTA - 62.5 & 125
Tablet

Composition…
Bose tan IP - 62.5 & 125 mg
Tablet
———-
**Pulmonary Arterial Hypertension:

Managing the Disease with Lifestyle Care and Bosvanta (Bosentan)**

Pulmonary Arterial Hypertension (PAH) is a serious and progressive condition characterized by increased blood pressure in the pulmonary arteries. This elevated pressure puts excessive strain on the heart, particularly the right ventricle, and if left untreated, may lead to heart failure and reduced quality of life.

Early diagnosis and a comprehensive treatment approach are essential to slow disease progression and improve patient outcomes.

The Role of Lifestyle Modification

Lifestyle management plays a crucial supportive role in PAH treatment.
Key measures include:
• Reduced salt intake, which helps prevent fluid retention
• Healthy and balanced eating, supporting overall cardiovascular health
• Regular medical follow-up and adherence to therapy

Less salt and mindful nutrition reduce the workload on the heart and complement pharmacological treatment.

Bosvanta (Bosentan) in PAH Management

Bosvanta contains Bosentan, an endothelin receptor antagonist that helps reduce pulmonary vascular resistance. By blocking the effects of endothelin—a substance that causes blood vessels to constrict—Bosentan improves blood flow through the lungs and reduces strain on the heart.

Bosvanta is available in:
• 62.5 mg
• 125 mg

These strengths allow physicians to individualize treatment based on patient needs and clinical response.

A Combined Approach for Better Outcomes

The management of Pulmonary Arterial Hypertension is most effective when medical therapy is combined with healthy lifestyle choices. Together, reduced salt intake, balanced nutrition, and appropriate pharmacological treatment such as Bosvanta help patients manage symptoms, improve functional capacity, and enhance quality of life.

Conclusion

PAH requires long-term, carefully monitored treatment. With early intervention, lifestyle discipline, and evidence-based therapy, patients can achieve better disease control and improved daily living.

Bosvanta should be used strictly under medical supervision.

02/01/2026

INDIS LAUNCHED NEW PRODUCT
Brand...

Fluventa M
FLUVENTA - M
Trusted Dual-Action Therapy for Anxiety, Depression & Psychosomatic Disorders

Indis, in association with Ind-Swift Laboratories Limited, introduces Fluventa M, a well-established and effective combination therapy for managing anxiety-depressive states and related psychosomatic conditions, providing a balanced approach to mental well-being.

Fluventa M combines two proven molecules that work synergistically to restore emotional balance, improve mood, and reduce anxiety-related symptoms, making it a widely trusted formulation in clinical practice for patients experiencing stress-related disorders affecting both mind and body.

Composition & Pharmacological Benefits
Each tablet of Fluventa M contains:
• Flupentixol 0.5 mg – A typical antipsychotic with anxiolytic and mood-elevating properties at low doses
• Melitracen 10 mg – A tricyclic antidepressant that improves mood, motivation, and emotional stability

Together, this combination offers:
• Rapid relief from anxiety and depressive symptoms
• Improvement in mood, energy, and concentration
• Better management of psychosomatic complaints

Indications
Fluventa M is commonly prescribed in:
• Anxiety and mild to moderate depression
• Psychosomatic disorders
• Stress-related emotional disturbances
• Depressive states with associated somatic symptoms
• Patients with fatigue, loss of interest, or emotional imbalance

Product Details
• Brand Name: Fluventa M
• Composition: Flupentixol 0.5 mg & Melitracen 10 mg Tablets
• Packing: 10 × 10 Tablets (Blister Pack)
• Case Size: 240 Boxes
• MRP: ₹98.00 per strip
• Manufactured by: Logos Pharma

Conclusion
Fluventa M offers a reliable, cost-effective, and clinically proven solution for managing anxiety-depressive disorders and psychosomatic conditions, ensuring effective symptom control while supporting long-term emotional well-being.

For business or product inquiries, please contact:
Email: indishealthcare@gmail.com

Indis Healthcare

30/01/2026

30/01/2026

26/01/2026

23/01/2026

18/01/2026

18/01/2026

18/01/2026

18/01/2026

14/01/2026

12/01/2026

05/01/2026

02/01/2026

Address

Website

Alerts

Contact The Practice

Shortcuts

Share

Category